Highlights
CP therapy might be a confident strategy choice for COVID-19 saving.
Tocilizumab and Anakinra have shown some benefits in patients with COVID-19.
Recent findings show that the HQC has no beneficial effects on COVID-19 patients.
hrsACE2, Ivermectin, and EIDD-2801 have exhibited an inhibitory effect against SARS-CoV-2.
Recent data show that the only remdesivir has a limited benefit in patients with COVID-19.